Cyclopentaimidazolones for the treatment of cancer
Provided herein are compounds useful for the treatment of various proliferative diseases. These compounds, as well as pharmaceutically acceptable salts thereof may be formulated in pharmaceutical compositions, and may be used in methods of treatment and/or prophylaxis of proliferative diseases, including cancer, and more specifically, pancreatic cancer.
1. A compound having the structure of formula (I):
wherein the “dashed” bond is a single or double bond;
R 1 is optionally substituted C 1-6 alkyl;
R 2 is C 6-12 aryl or C 7-13 arylalkyl optionally substituted one to three times with halogen, —R, —OR, —(CH 2 OCH 2 ) m —(CH 2 ) p —N 3 , —(CH 2 CH 2 O) n —(CH 2 ) p —N 3 , —CN, or combinations thereof;
R 3 is hydrogen, optionally substituted C 1-6 alkyl, —(CH 2 OCH 2 ) m —(CH 2 ) p —N 3 , or —(CH 2 CH 2 O) n —(CH 2 ) p —N 3 ;
R is independently at each occurrence optionally substituted C 1-6 alkyl; and
m is independently selected at each occurrence from 0-5 and p is independently selected at each occurrence from 0-5;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 having the structure of formula (Ia) or formula (Ib) or formula (Id):
3. The compound according to claim 1 , wherein R 1 is C 4 alkyl.
4. The compound according to claim 1 , wherein R 2 is phenyl or benzyl optionally substituted once with —F, —Cl, —CN, —CH 3 , or —OCH 3 .
5. The compound according to claim 1 wherein R 3 is hydrogen, methyl, or ethyl.
6. The compound according to claim 1 , wherein the “dashed” bond is a double bond.
7. The compound according to claim 1 , wherein the compound is selected from:
8. A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier, excipient, and/or diluent.
9. A method of killing a cancer cell comprising contacting said cancer cell with a compound according to claim 1 .
10. The method according to claim 9 , wherein said cancer cell is in vitro or in vivo.
11. A method of treatment of cancer comprising administering an effective amount of the compound according to claim 1 to a subject in need thereof, wherein the cancer is melanoma, gastrointestinal stromal tumors, lung cancer, skin cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, thyroid cancer, hematological malignancy, papillary thyroid carcinoma, cholangiocarcinoma, metastatic melanoma, glioblastoma multiform, pancreatic cancer, or acute myelogenous leukemia.
12. The method according to claim 11 , wherein said cancer is pancreatic cancer.
13. The method according to claim 11 , wherein said compound is coadministered with another anticancer agent.
14. The method according to claim 13 , wherein said anticancer agent is vemurafenib or a pharmaceutically acceptable salt thereof.
15. The method according to claim 13 , wherein said anticancer agent is a MEK inhibitor.
16. The method according to claim 15 , wherein said MEK inhibitor is selected from trametinib, cobimetinib, selumetinib, binimetinib, or pharmaceutically acceptable salts thereof.
17. The method according to claim 11 , wherein said compound is administered intravenously, intramuscularly, subcutaneously, topically, orally, intraperitoneally, intraorbitally, by implantation, by inhalation, intrathecally, intraventricularly, or intranasally.